Note: Descriptions are shown in the official language in which they were submitted.
CA 02953396 2016-12-21
WO 2016/004170 PCT/1JS2015/038774
ABUSE DETERRENT IMMEDIATE RELEASE FORMULATIONS COMPRISING NON-
CELLULOSE POLYSACCHARIDES
FIELD
[0001] The present disclosure generally relates to pharmaceutical
compositions that provide immediate release of active ingredients and have
abuse
deterrent properties.
BACKGROUND
[0002] Abuse of prescription drugs (particularly opioids) has become
a
serious societal problem. Such abuse places an enormous economic burden on
society
due to increased health care, work place, and criminal justice costs. Several
routes of
administration are commonly attempted by abusers. For example, the oral solid
dosage
form may be crushed or pulverized into a powder and administered intranasally
(i.e.,
snorted) or dissolved in a suitable solvent (e.g., water) and administered
parenterally
(i.e., injected intravenously).
[0003] Attempts have been made to diminish the abuse of opioid solid
dosage forms. One approach has been to include in the dosage form an opioid
antagonist that is not orally active but will substantially block the
analgesic effects of the
opioid if one attempts to dissolve the opioid and administer it parenterally.
Another
approach has been to include gel-forming high molecular weight polymers that
confer
plasticity to the dosage form rendering them difficult to crush and pulverize
into a
powder. These high molecular weight polymers, however, retard the release of
the
active ingredient from the dosage forms, making them unsuitable for immediate
release
formulations.
[0004] Thus, there is a need for oral solid dosage forms that provide
immediate release of the active ingredient yet are resistant to abuse.
1
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
SUMMARY
[0005] One aspect of the present disclosure encompasses a
pharmaceutical composition comprising at least one active pharmaceutical
ingredient
(API) or a pharmaceutically acceptable salt thereof, at least one non-
cellulose
polysaccharide, at least one hydrophilic gelling polymer, and an effervescent
system.
The pharmaceutical composition provides immediate release of the API. In some
embodiments, at least about 70% of the API is released within about 45 minutes
when
dissolution is measured using an USP-approved in vitro release procedure. The
pharmaceutical composition has abuse deterrent properties. In some instances,
a
plurality of particles having an average diameter greater than about 250
microns is
formed when the pharmaceutical composition is crushed, ground, or pulverized.
In
other instances, the pharmaceutical composition is resistant to forming a fine
powder
when subjected to crushing, grinding, cutting, or pulverizing. In still other
instances, the
pharmaceutical composition is resistant to extraction with an aqueous solvent.
[0006] The non-cellulose polysaccharide can be a natural gum,
hemicellulose, pectin, chitin, starch, or a combination thereof. In general,
the non-
cellulose polysaccharide is present in an amount from about 2% to about 60% by
weight
of the pharmaceutical composition. The hydrophilic gelling polymer can be a
cellulose
ether, a polyalkylene oxide, a polyacrylic acid, or a combination thereof.
Typically, the
hydrophilic gelling polymer is present in an amount from about 5% to about 80%
by
weight of the pharmaceutical composition. The effervescent system comprises an
acid
component and a base component. The acid component can be an organic acid, an
inorganic acid, or a combination thereof. The base component can be an alkali
metal
bicarbonate, an alkaline earth metal bicarbonate, an alkali metal carbonate,
an organic
carbonate, or a combination thereof. In general, the effervescent system is
present in
an amount from about 20% to about 90% by weight of the pharmaceutical
composition.
In various embodiments, the API has a potential for abuse. In some instances
the API
is an opioid or a combination of an opioid and a non-opioid analgesic. In
other
instances the API is oxycodone, oxymorphone, hydrocodone, hydromorphone,
codeine,
or morphine.
2
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
[0007] In specific embodiments, the non-cellulose polysaccharide is
glucomannan, xanthan gum, or a combination thereof; the hydrophilic gelling
polymer is
polyethylene oxide, hydroxypropylmethylcellulose, hydroxypropyl cellulose,
sodium
carboxymethylcellulose, or a combination thereof; the effervescent system
comprises
an organic acid and an alkali metal bicarbonate/carbonate, and the API is
oxycodone,
oxymorphone, hydrocodone, hydromorphone, codeine, or morphine. In other
embodiments, the non-cellulose polysaccharide is a combination of glucomannan
and
xanthan gum, the hydrophilic gelling polymer is a combination of polyethylene
oxides,
hydroxypropylmethylcellulose, and sodium carboxymethylcellulose, the
effervescent
system comprises an organic acid and an alkali metal bicarbonate/carbonate,
and the
API is oxycodone. The amount of the non-cellulose polysaccharide can range
from
about 5% to about 40% by weight of the pharmaceutical composition. The amount
of
the hydrophilic gelling polymer can range from about 10% to about 50% by
weight of the
pharmaceutical composition. The amount of the effervescent system can range
from
about 30% to about 60% by weight of the pharmaceutical composition. In some
embodiments, the pharmaceutical composition can further comprise one or more
lubricants. For example, the lubricant can be a metal stearate. In other
embodiments,
the pharmaceutical composition can further comprise one or more preservatives.
In still
further embodiments, the pharmaceutical composition can further comprise a
water-
soluble film coating.
[0008] In further embodiments, the pharmaceutical composition is a
solid
dosage form. The solid dosage form can be a tablet. The solid dosage from can
be
prepared by a process comprising (a) forming a mixture comprising the API or
pharmaceutically acceptable salt thereof, the non-cellulose polysaccharide,
the
hydrophilic gelling polymer, and the effervescent system, (b) forming the
mixture into a
solid dosage unit, and (c) heating the solid dosage unit to yield the solid
dosage form.
In general, the heating step occurs at a temperature of less than about 90 C.
[0009] Other aspects and iterations of the disclosure are described
in
more detail below.
3
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
DETAILED DESCRIPTION
[0010] The present disclosure provides pharmaceutical compositions
that
provide rapid release of the active ingredients and have abuse deterrent
properties. In
particular, the pharmaceutical compositions comprise non-cellulose
polysaccharides
and hydrophilic gelling polymers in combination with an effervescent system
comprising
an acid component and a base component. It was unexpectedly discovered that
the
combination of non-cellulose polysaccharides, hydrophilic gelling polymers,
and the
effervescent system makes the compositions resistant to crushing into fine
powders
and/or extracting with suitable solvents at a variety of temperatures, while
still providing
immediate release of the active ingredient(s). The present disclosure also
provides
processes for preparing the immediate release, abuse deterrent pharmaceutical
compositions disclosed herein.
(I) Pharmaceutical Compositions
[0011] One aspect of the present disclosure provides abuse deterrent
pharmaceutical compositions that provide immediate release of the active
pharmaceutical ingredients. Detailed below are the components of the
compositions,
release characteristics of the compositions, and abuse deterrent properties of
the
compositions.
(a) Components
[0012] The pharmaceutical compositions disclosed herein comprise at
least one non-cellulose polysaccharide, at least one hydrophilic gelling
polymer, and an
effervescent system. The combination of the non-cellulose polysaccharide, the
hydrophilic gelling polymers, and the effervescent system yields a composition
that has
abuse deterrent properties (e.g., is difficult to crush into a fine powder or
extract with an
aqueous solvent) but which also provides rapid and immediate release of the
active
ingredient.
4
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
(I) Non-cellulose polysaccharides
[0013] A variety of non-cellulose polysaccharides may be included in
the
pharmaceutical compositions disclosed herein. Suitable polysaccharides
include,
without limit, natural gums, hemicelluloses (such as xyloglucans, xylans, and
mannans),
pectins (e.g., derived from citrus, apples, pears gooseberries, and the like),
chitins,
starches (e.g., derived from corn, potato, rice, and so forth), glycogen,
chrysolaminarin,
derivatives thereof, and combinations thereof.
[0014] In certain embodiments, the non-cellulose polysaccharide is a
natural gum or a combination of natural gums. Natural gums are non-cellulose
polysaccharides derived from botanical sources, seaweeds, or produced via
bacterial
fermentation. Non-limiting examples of plant-derived natural gums include
albizia gum,
aloe mucilage, beta-glucan, chicle gum, dammar gum, fenugreek gum,
glucomannan,
guar gum, gum arabic (also called acacia gum), gum copal, gum ghatti, gum
tragacanth,
hakea gum, Hibiscus rosasinensis gum, honey locust gum, hupu gum, karaya gum,
khaya gum, Lepidium sativum gum, locust bean gum, mastic gum, Mimosa scabrella
gum, Mimosa pudica gum, okra gum, psyllium seed husks (also called ispaghula
husk),
spruce gum, Sterculia foetida gum, tamarind gum, tara gum, and derivatives of
any of
the foregoing. Examples of natural gums derived from seaweeds include, without
limit,
alginate or alginic acid, fucoidan, and laminarin derived from brown seaweeds,
and agar
and carrageenans derived from red seaweeds. Non-limiting examples of natural
gums
produced by bacterial fermentation include xanthan gum, gellan gum, dextran,
welan
gum, diutan gum, pullulan, and derivatives thereof.
[0015] In specific embodiments, the non-cellulose polysaccharide is a
natural gum. In one embodiment, the non-cellulose polysaccharide may be a
glucomannan. Glucomannans are linear polysaccharides composed of [3-1,4 linked
D-
mannose and D-glucose residues (with acetyl side branches on some of the
backbone
units) that are derived from softwoods, roots, tubers, and plant bulbs. The
man nose to
glucose ratio depends upon the source of the glucomannan. For example, konjac
glucomannan, which is derived from the tubers of Amorphophallus konjac K.
Koch, has
a mannose:glucose ratio of 1.6:1, whereas those extracted from Scotch pine or
orchids
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
have ratios of 2.1:1 or 3.6:1, respectively. In a particular iteration, the
glucomannan
may be konjac glucomannan. In another embodiment, the non-cellulose
polysaccharide
may be a combination of glucomannan and xanthan gum.
[0016] In general, the non-cellulose polysaccharide has a high
molecular
weight and forms a viscous mixture or gel upon contact with water or an
aqueous
solution. In some embodiments, the polysaccharide may have an average
molecular
weight of greater than about 200,000, greater than about 500,000, greater than
about
1,000,000, greater than about 2,000,000, or greater than about 4,000,000.
[0017] The amount of the non-cellulose polysaccharide present in the
pharmaceutical composition, can and will vary depending upon the desired
properties of
the pharmaceutical composition, as well as the identity and amounts of other
components present in the dosage form. In general, the amount of non-cellulose
polysaccharide in the composition may range from about 2% to about 60% by
weight of
the pharmaceutical composition. In various embodiments, the amount of the non-
cellulose polysaccharide may range from about 3% to about 50%, from about 5%
to
about 40%, from about 6% to about 30%, or from about 10% to about 25% by
weight of
the pharmaceutical composition. In some embodiments, the amount of non-
cellulose
polysaccharide may range from 2% to about 10%, from about 10% to about 15%,
from
about 15% to about 20%, from about 20% to about 25%, from about 25% to about
40%,
or from about 40% to about 60% by weight of the pharmaceutical composition. In
particular embodiments, the amount of non-cellulose polysaccharide may be
about 25%
or less by weight of the pharmaceutical composition. In specific embodiments,
the
amount of non-cellulose polysaccharide in the composition may range from about
5% to
about 40% by weight of the pharmaceutical composition.
(ii) Hydrophilic gelling polymers
[0018] The pharmaceutical compositions disclosed herein also comprise
at
least one hydrophilic gelling polymer. The term "hydrophilic gelling polymer"
refers to a
polymer with affinity for water such that it readily absorbs water or an
aqueous solution
6
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
and/or swells when in contact with water or an aqueous solution to form a
viscous
mixture or gel.
[0019] A variety of hydrophilic gelling polymers are suitable for use
in the
pharmaceutical solid dosage forms. The polymer may be natural, semi-synthetic,
or
synthetic. Non-limiting examples of suitable hydrophilic gelling polymers
include
cellulose ethers, polyalkylene oxides, polyacrylic acids, polyamines,
polyolefinic
alcohols, polyvinyl lactams, derivatives thereof, and combinations thereof.
[0020] In some embodiments, the hydrophilic gelling polymer may be a
cellulose ether. Cellulose ethers are cellulose derivatives in which the
hydrogen atoms
of hydroxyl groups are replaced with alkyl groups. The degree of substitution
can and
will vary. Non-limiting examples of suitable cellulose ethers include
hydroxypropyl cellulose (H PC), hydroxypropylmethylcellulose (HPMC),
carboxymethyl cellulose (CMC) (e.g., sodium carboxymethylcellulose),
methylcellulose,
hydroxyethylcellulose, hydroxyethylmethylcellulose,
methylhydroxyethylcellulose, and
the like. In specific embodiments, the cellulose ether may be
hydroxypropylcellulose,
hydroxypropylmethylcellulose, sodium carboxymethyl cellulose, or combinations
thereof.
The average molecular weight of the cellulose ether may range from about
20,000 to
about 1,500,000. In various embodiments, the weight average molecular weight
of the
cellulose ether may be about 30,000, about 100,000, about 250,000, about
850,000, or
about 1,150,000.
[0021] In other embodiments, the hydrophilic gelling polymer may be a
polyalkylene oxide such as polyethylene oxide (PEO), polypropylene oxide
(PPO),
derivatives thereof, copolymers thereof, or combinations thereof. In
particular
embodiments, the hydrophilic gelling polymer may be a polyethylene oxide or a
combination of polyethylene oxides of different molecular weights. The average
molecular weight of the polyethylene oxide may range from about 100,000 to
about
10,000,000. In certain embodiments, the polyethylene oxide may have an average
molecular weight of about 100,000 or about 4,000,000.
[0022] In still other embodiments, the hydrophilic polymer may be a
polyacrylic acid. Suitable polyacrylic acids include carbonners, which are
homopolymers
7
of acrylic acid cross linked with polyalcohol ally! ethers (e.g., allyl ether
pentaerythritol,
allyl ether of sucrose, or allyl ether of propylene), and polycarbophil, which
is a
homopolymer of acrylic acid cross linked with divinyl glycol. Available
carbomers
include CarbopolTM 910, 934, 940, 941, and 943P (the codes are indicators of
molecular weight and the specific components of the polymer).
[0023] In additional embodiments, the hydrophilic gelling polymer may
be
a polyamine such as polyethyleneimine, polyvinylamine, or the like. In still
further
embodiments, the hydrophilic gelling polymer may be a polyolefinic alcohol
(such as
polyvinyl alcohol), or a polyvinyl lactam (such as, e.g.,
polyvinylpyrrolidone, polyvinyl
caprolactam, and the like). The average molecular weight of said polymers may
range
from about 20,000 to about 1,300,000.
[0024] In specific embodiments, the hydrophilic gelling polymer may
comprise a combination of one or more cellulose ethers (e.g.,
hydroxypropylcellulose,
hydroxypropylmethylcellulose, sodium carboxymethylcellulose) and one or more
polyethylene oxides having different molecular weights.
[0025] The amount of the hydrophilic gelling polymer present in the
pharmaceutical composition can and will vary depending upon the desired
properties of
the pharmaceutical composition, as well as the identity and amounts of other
components present in the pharmaceutical composition. In general, the amount
of the
hydrophilic gelling polymer may range from about 5% to about 80% by weight of
the
pharmaceutical composition. In various embodiments, the amount of the
hydrophilic
gelling polymer in the composition may range from about 6% to about 70%, from
about
8% to about 60%, from about 10% to about 50%, from about 15% to about 40%, or
from about 20% to about 35% by weight of the pharmaceutical composition. In
certain
embodiments, the amount of the hydrophilic gelling polymer may range from
about 5%
to about 20%, from about 20% to about 25%, from about 25% to about 30%, from
about
30% to about 40%, from about 40% to about 60%, or from about 60% to about 80%
by
weight of the pharmaceutical composition. In specific embodiments, the amount
of the
hydrophilic gelling polymer may range from about 10% to about 50% by weight of
the
pharmaceutical composition.
8
Date Recue/Date Received 2021-09-27
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
(Hi) Effervescent system
[0026] The pharmaceutical composition disclosed herein also comprises
an effervescent system. As used herein, an "effervescent system" refers to a
system
generally comprising an acid component and a base component, wherein the
system
liberates carbon dioxide upon contact with an aqueous solution. Without being
bound
by any particular theory, it is believed that the effervescent system
facilitates rapid
dissolution of the API from the composition comprising the combination of non-
cellulose
polysaccharide(s) and hydrophilic gelling polymer(s).
[0027] The acid component of the effervescent system may be an
organic
acid, an inorganic acid, or a combination thereof. Non-limiting examples of
suitable
acids include adipic acid, ascorbic acid, benzoic acid, citric acid, fumaric
acid, glutaric
acid, lactic acid, lauric acid, malic acid, maleic acid, nnalonic acid, oxalic
acid, phthalic
acid, sorbic acid, succinic acid, tartaric acid, ammonium phosphate, potassium
bitartrate, potassium phosphate, dipotassium phosphate, disodium
pyrophosphate,
sodium acid pyrophosphate, sodium phosphate, disodium phosphate, and
combinations
thereof. In specific embodiments, the acid component of the effervescent
system may
be an organic acid. In one iteration, the acid component may be tartaric acid.
In other
embodiments, the acid component of the effervescent system may be an inorganic
acid.
[0028] In some embodiments, the acid component of the effervescent
system may be co-processed with a polyalkylene glycol (such as, e.g.,
polyethylene
glycol), a poloxanner (which is a difunctional, tri-block copolymer of
polyethylene oxide
and polypropylene oxide), or combinations thereof. Non-limiting examples of
suitable
polyethylene glycols (PEG) include PEG 1000, PEG 2000, PEG 3300, PEG 4000, PEG
5000, PEG 6000, PEG 8000, PEG 10,000, PEG 20,000, PEG 30,000, derivatives
thereof, copolymers thereof, and combinations thereof. Examples of suitable
polaxamers (which are available under the trade names KOLLIPHORTM or PLURONIC
)
include, without limit, Poloxamer 101, 105, 108, 122, 123, 124, 181, 182, 183,
184, 185,
188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334,
335, 338,
401, 402, 403, and 407, wherein the first two digits multiplied by 100 give
the
approximate molecular mass and the last digit multiplied by 10 gives the
percentage of
9
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
the polyoxyethylene oxide content. The acid and the polyalkylene glycol and/or
poloxamer may be co-processed by a variety of means including, without limit,
hot melt
granulation, fluidized hot melt granulation, hot melt mixing, wet granulation,
liquid spray
mixing, and the like. The amount of polyalkylene glycol and/or poloxamer co-
processed
with the acid can and will vary. In general, the weight to weight ratio of the
acid to the
polyalkylene glycol and/or poloxamer may range from about 1:0.01 to about
1:0.5.
[0029] The base component of the effervescent system may be a
bicarbonate, a carbonate, or a combination thereof. In various embodiments,
the base
may be an alkali metal bicarbonate, an alkaline earth metal bicarbonate, an
alkali metal
carbonate, an organic carbonate, or combinations thereof. Non-limiting
examples of
suitable bases include ammonium bicarbonate, calcium bicarbonate, lithium
bicarbonate, magnesium bicarbonate, potassium bicarbonate, sodium bicarbonate,
arginine carbonate, ammonium carbonate, calcium carbonate, lysine carbonate,
potassium magnesium carbonate, sodium carbonate, sodium glycine carbonate,
sodium
sesquicarbonate, zinc carbonate, and combinations thereof. In exemplary
embodiments, the base may be an alkali metal bicarbonate. In one exemplary
embodiment, the base may be sodium bicarbonate. In another exemplary
embodiment,
the base may be heat-treated sodium bicarbonate (for example EfferSoda512).
[0030] The mole to mole ratio of the acid component to the base
component in the effervescent system may also vary depending, for example,
upon the
identity of the acid and the base. In general, the mole to mole ratio of the
acid
component to the base component in the effervescent system may range from
about
1:0.2 to about 1:5. For example, the mole to mole ratio of the acid component
to the
base component in the effervescent system may be about 1:0.2, about 1:0.25,
about
1:0.33, about 1:0.5, about 1:1, about 1:2, about 1:3, about 1:4, about 1:5 or
any ratio in
between. In one exemplary embodiment, the mole to mole ratio of the acid
component
to the base component in the effervescent system may range from about 1:1 to
about
1:3. In another exemplary embodiment, the mole to mole ratio of the acid
component to
the base component in the effervescent system may be about 1:2.
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
[0031] The amount of the effervescent system present in the
pharmaceutical composition can and will vary depending upon the identity of
the other
components and the desired properties of the pharmaceutical composition. In
general,
the amount of the effervescent system may range from about 20% to about 90% by
weight of the pharmaceutical composition. In various embodiments, the amount
of the
effervescent system in the composition may range from about 20% to about 80%,
from
about 25% to about 70%, from about 30% to about 60%, or from about 40% to
about
50% by weight of the pharmaceutical composition. In certain embodiments, the
amount
of the effervescent system may range from about 20% to about 30%, from about
30% to
about 40%, from about 40% to about 50%, from about 50% to about 60%, from
about
60% to about 70%, from about 70% to about 80%, or from about 80% to about 90%
by
weight of the pharmaceutical composition. In specific embodiments, the amount
of the
effervescent system may range from about 30% to about 60% by weight of the
pharmaceutical composition.
(iv) Additional components
[0032] In some embodiments, the pharmaceutical composition disclosed
herein may also comprise a lubricant. Non-limiting examples of suitable
lubricants
include metal stearate such as magnesium stearate, calcium stearate, zinc
stearate, a
polyethylene glycol, a poloxamer, colloidal silicon dioxide, glyceryl
behenate, light
mineral oil, hydrogenated vegetable oils, magnesium lauryl sulfate, magnesium
trisilicate, polyoxyethylene monostearate, sodium stearoyl fumarate, sodium
stearyl
fumarate, sodium benzoate, sodium lauryl sulfate, stearic acid, sterotex,
talc, and
combinations thereof. In specific embodiments, the lubricant may be a metal
stearate.
In one iteration, the lubricant may be magnesium stearate.
[0033] The amount of lubricant present in the pharmaceutical
composition
can and will vary depending upon the identities and amounts of other
components in the
composition. In embodiments in which a lubricant is present, the amount of
lubricant
generally ranges from about 0.1% to about 3% by weight of the pharmaceutical
composition. In various embodiments, the amount of lubricant present in the
11
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
composition may range from about 0.1% to about 0.3%, from about 0.3 to about
1%, or
from about 1% to about 3% by weight of the composition. In specific
embodiments, the
amount of lubricant present in the composition may range from about 0.2% to
about 2%
by weight of the pharmaceutical composition. In one specific embodiment, the
amount
of lubricant present in the composition may range from about 0.3% to about 1%
by
weight of the pharmaceutical composition.
[0034] In additional embodiments, the pharmaceutical composition
disclosed herein may also comprise a preservative. Non limiting examples of
suitable
preservatives include antioxidants (such as, e.g., alpha-tocopherol, ascorbyl
palmitate,
butylated hydroxyanisole, butylated hydroxytoluene, citric acid,
dihydroguaretic acid,
potassium ascorbate, potassium sorbate, propylgallate, sodium bisulfate,
sodium
isoascorbate, sodium metabisulfate, sorbic acid, 4-chloro-2,6-
ditertiarybutylphenol, and
so forth), antimicrobials (such as, e.g., benzyl alcohol, cetylpryidine
chloride, glycerine,
parabens, propylene glycol, potassium sorbate, sodium benzoate, sorbic acid,
sodium
propionate, and the like), and combinations thereof. In specific embodiments,
the
preservative may be butylated hydroxytoluene, citric acid, or a combination
thereof.
[0035] The amount of preservative present in the pharmaceutical
composition can and will vary. In embodiments in which a preservative is
present, the
amount of preservative in the composition may range from about 0.005% to about
3%
by weight of the pharmaceutical composition. In various embodiments, the
amount of
preservative may range from about 0.005% to about 0.03%, from about 0.03 to
about
0.1%, from about 0.1% to about 0.3%, from about 0.3% to about 1.0%, or from
about
1% to about 3% by weight of the composition. In specific embodiments, the
amount of
preservative may range from about 0.01 /0 to about 1% by weight of the
pharmaceutical
composition.
(v) API
[0036] The pharmaceutical composition disclosed herein comprises at
least one API or a pharmaceutically acceptable salt thereof. Suitable APIs
include,
without limit, opioid analgesic agents (e.g., adulmine, alfentanil,
allocryptopine,
12
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
allylprodine, alphaprodine, anileridine, aporphine, benzylmorphine, berberine,
bicuculine, bicucine, bezitrannide, buprenorphine, bulbocaprine, butorphanol,
clonitazene, codeine, desonnorphine, dextronnoramide, dezocine, diampronnide,
diannorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol,
dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine,
ethoheptazine,
ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin,
hydrocodone,
hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol,
levophenacylnnorphan, lofentanil, meperidine, meptazinol, metazocine,
methadone,
metopon, morphine, myrophine, narceine, nicomorphine, norlevorphanol,
normethadone, nalorphine, nalbuphine, nalmefene, normorphine, norpipanone,
opium,
oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan,
phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol,
properidine, propoxyphene, sufentanil, tapentadol, tilidine, and tramadol);
opioid
antagonists (e.g., naloxone, naltrexone, alvimopan, cyprodime, diprenorphine,
gemazocine, 5'-guanidinonaltrindole, levallorphan, methylnaltrexone,
naldemedine,
nalmexone, nalorphine, naloxazone, naloxol, naloxonazine, 63-naltrexol-d4,
naltriben,
naltrindole, norbinaltorphimine, oxilorphan, quadazocine, and sannidorphan);
non-opioid
analgesic agents (e.g., acetylsalicylic acid, acetaminophen, paracetamol,
ibuprofen,
ketoprofen, indomethacin, diflunisol, naproxen, ketorolac, dichlophenac,
tolmetin,
sulindac, phenacetin, piroxicam, and mefamanic acid); anti-inflammatory agents
(e.g.,
glucocorticoids such as alclometasone, fluocinonide, methylprednisolone,
triamcinolone
and dexamethasone; non-steroidal anti-inflammatory agents such as celecoxib,
deracoxib, ketoprofen, lumiracoxib, meloxicam, parecoxib, rofecoxib, and
valdecoxib);
antitussive agents (e.g., dextromethorphan, codeine, hydrocodone, caramiphen,
carbetapentane, and dextromethorphan); antipyretic agents (e.g.,
acetylsalicylic acid
and acetaminophen); antibiotic agents (e.g., aminoglycosides such as,
amikacin,
gentamicin, kanamycin, neomycin, netilmicin, streptomycin, and tobramycin;
carbecephem such as loracarbef; carbapenems such as certapenem, innipenem, and
meropenem; cephalosporins such as cefadroxil cefazolin, cephalexin, cefaclor,
cefamandole, cephalexin, cefoxitin, cefprozil, cefuroxi me, cefixime,
cefdinir, cefditoren,
13
cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime,
and
ceftriaxone; macrolides such as azithromycin, clarithromycin, dirithromycin,
erythromycin, and troleandomycin; monobactam; penicillins such as amoxicillin,
ampicillin, carbenicillin, cloxacillin, dicloxacillin, nafcillin, oxacillin,
penicillin G, penicillin
V, piperacillin, and ticarcillin; polypeptides such as bacitracin, colistin,
and polymyxin B;
quinolones such as ciprofloxacin, enoxacin, gatifloxacin, levofloxacin,
lomefloxacin,
moxifloxacin, norfloxacin, ofloxacin, and trovafloxacin; sulfonamides such as
mafenide,
sulfacetamide, sulfamethizole, sulfasalazine, sulfisoxazole, and trimethoprim-
sulfamethoxazole; tetracyclines such as demeclocycline, doxycycline,
minocycline, and
oxytetracycline); antimicrobial agents (e.g., ketoconazole, amoxicillin,
cephalexin,
miconazole, econazole, acyclovir, and nelfinavir); antiviral agents (e.g.,
acyclovir,
gangciclovir, oseltamivir, and relenzaTm); steroids (e.g., estradiol,
testosterone, cortisol,
aldosterone, prednisone, and cortisone); amphetamine stimulant agents (e.g.,
amphetamine and amphetamine-like drugs); non-amphetamine stimulant agents
(e.g.,
methylphenidate, nicotine, and caffeine); laxative agents (e.g., bisacodyl,
casanthranol,
senna, and castor oil); anti-nausea agents (e.g., dolasetron, granisetron,
ondansetron,
tropisetron, meclizine, and cyclizine); anorexic agents (e.g., fenfluramine,
dexfenfluramine, mazindol, phentermine, and aminorex); antihistaminic agents
(e.g.,
phencarol, cetirizine, cinnarizine, ethamidindole, azatadine, brompheniramine,
hydroxyzine, and chlorpheniramine); antiasthmatic agents (e.g., zileuton,
montelukast,
omalizumab, fluticasone, and zafirlukast); antidiuretic agents (e.g.,
desmopressin,
vasopressin, and lypressin); antimigraine agents (e.g., naratriptan,
frovatriptan,
eletriptan, dihydroergotamine, zolmitriptan, almotriptan, and sumatriptan);
antispasmodic agents (e.g., dicyclomine, hyoscyamine, and peppermint oil);
antidiabetic agents (e.g., methformin, acarbose, miglitol, pioglitazone,
rosiglitazone,
nateglinide, repaglinide, mitiglinide, saxagliptin, sitagliptine,
vildagliptin, acetohexamide,
chlorpropamide, gliclazide, glimepiride, glipizide, glyburide, tolazamide, and
tolbutamide); respiratory agents (e.g., albuterol, ephedrine, metaproterenol,
and
terbutaline); sympathomimetic agents (e.g., pseudoephedrine, phenylephrine,
phenylpropanolamine, epinephrine, norepinephrine, dopamine, and ephedrine); H2
14
Date Recue/Date Received 2021-09-27
blocking agents (e.g., cimetidine, famotidine, nizatidine, and ranitidine);
antihyperlipidemic agents (e.g., clofibrate, cholestyramine, colestipol,
fluvastatin,
atorvastatin, genfibrozil, lovastatin, niacin, pravastatin, fenofibrate,
colesevelam, and
simvastatin); antihypercholesterol agents (e.g., lovastatin, simvastatin,
pravastatin,
fluvastatin, atorvastatin, cholestyramine, colestipol, colesevelam, nicotinic
acid,
gemfibrozil, and ezetimibe); cardiotonic agents (e.g., digitalis,
ubidecarenone, and
dopamine); vasodilating agents (e.g., nitroglycerin, captopril, dihydralazine,
diltiazem,
and isosorbide dinitrate); vasoconstricting agents (e.g., dihydroergotoxine
and
dihydroergotamine); anticoagulants (e.g., warfarin, heparin, and Factor Xa
inhibitors);
sedative agents (e.g., amobarbital, pentobarbital, secobarbital,
clomethiazole,
diphenhydramine hydrochloride, and alprazolam); hypnotic agents (e.g.,
zaleplon,
zolpidem, eszopiclone, zopiclone, chloral hydrate, and clomethiazole);
anticonvulsant
agents (e.g., lamitrogene, oxycarbamezine, phenytoin, mephenytoin,
ethosuximide,
methsuccimide, carbamazepine, valproic acid, gabapentin, topiramate,
felbamate, and
phenobarbital); muscle relaxing agents (e.g., baclofen, carisoprodol,
chlorzoxazone,
cyclobenzaprine, dantrolene sodium, metaxalone, orphenadrine, pancuronium
bromide,
and tizanidine); antipsychotic agents (e.g., phenothiazine, chlorpromazine,
fluphenazine, perphenazine, prochlorperazine, thioridazine, trifluoperazine,
haloperidol,
droperidol, pimozide, clozapine, olanzapine, risperidone, quetiapine,
ziprasidone,
melperone, and paliperidone); antianxiolitic agents (e.g., lorazepam,
alprazolam,
clonazepam, diazepam, buspirone, meprobamate, and flunitrazepam);
antihyperactive
agents (e.g., methylphenidate, amphetamine, and dextroamphetamine); antihyper-
tensive agents (e.g., alpha-methyldopa, chlortalidone, reserpine,
syrosingopine,
rescinnamine, prazosin, phentolamine, felodipine, propanolol, pindolol,
labetalol,
clonidine, captopril, enalapril, and lisonopril); anti-neoplasia agents (e.g.,
taxolTM,
actinomycin, bleomycin A2, mitomycin C, daunorubicin, doxorubicin, epirubicin,
idarubicin, and mitoxantrone); soporific agents (e.g., zolpidem tartrate,
eszopiclone,
ramelteon, and zaleplon); tranquilizer agents (e.g., alprazolam, clonazepam,
diazepam,
flunitrazepam, lorazepam, triazolam, chlorpromazine, fluphenazine,
haloperidol,
loxapine succinate, perphenazine, prochlorperazine, thiothixene, and
trifluoperazine);
Date Recue/Date Received 2021-09-27
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
decongestant agents (e.g., ephedrine, phenylephrine, naphazoline, and
tetrahydrozoline); beta blockers (e.g., levobunolol, pindolol, tinnolol
nnaleate, bisoprolol,
carvedilol, and butoxannine); alpha blockers (e.g., doxazosin, prazosin,
phenoxybenzamine, phentolamine, tamsulosin, alfuzosin, and terazosin); non-
steroidal
hormones (e.g., corticotropin, vasopressin, oxytocin, insulin, oxendolone,
thyroid
hormone, and adrenal hormone); erectile disfunction improvement agents; herbal
agents (e.g., glycyrrhiza, aloe, garlic, nigella sativa, rauwolfia, St John's
wort, and
valerian); enzymes (e.g., lipase, protease, amylase, lactase, lysozyme, and
urokinase);
humoral agents (e.g., prostaglandins, natural and synthetic, for example,
PGE1,
PGE2alpha, PGF2alpha, and the PGE1 analog misoprostol); psychic energizers
(e.g.,
3-(2-aminopropy)indole and 3-(2-aminobutyl)indole); nutritional agents;
essential fatty
acids; non-essential fatty acids; vitamins; minerals; and combinations
thereof.
[0037] Any of the above-mentioned APIs may be incorporated in the
pharmaceutical composition described herein in any suitable form, such as, for
example, as a pharmaceutically acceptable salt, uncharged or charged molecule,
molecular complex, solvate or hydrate, prodrug, and, if relevant, isomer,
enantiomer,
racemic mixture, and/or mixtures thereof. Furthermore, the API may be in any
of its
crystalline, semi-crystalline, amorphous, or polymorphous forms.
[0038] In one embodiment, the API in the pharmaceutical composition
may
have a potential for abuse. For example, the API may be an opioid analgesic
agent, a
stimulant agent, a sedative agent, a hypnotic agent, an antianxiolitic agent,
or a muscle
relaxing agent.
[0039] In another embodiment, the API in the pharmaceutical
composition
may be a combination of an opioid analgesic and a non-opioid analgesic.
Suitable
opioid and non-opioid analgesics are listed above.
[0040] In a further embodiment, the API in the pharmaceutical
composition
may be a combination of an opioid analgesic and an opioid antagonist, examples
of
which are listed above.
[0041] In a specific embodiment, the API in the pharmaceutical
composition may be an opioid analgesic. Exemplary opioid analgesics include
16
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
oxycodone, oxymorphone, hydrocodone, hydromorphone, codeine, and morphine. In
one specific embodiment, the API may be oxycodone hydrochloride. In another
specific
embodiment, the API may be oxymorphone hydrochloride.
[0042] The amount of the API in the pharmaceutical composition can
and
will vary depending upon the active agent. In embodiments in which the API is
an
opioid analgesic, the amount of opioid in the pharmaceutical composition may
range
from about 2 mg to about 160 mg. In various embodiments, the amount of opioid
in the
pharmaceutical composition may range from about 2 mg to about 10 mg, from
about 10
mg to about 40 mg, from about 40 mg to about 80 mg, or from about 80 mg to
about
160 mg. In certain embodiments, the amount of opioid in the pharmaceutical
composition may be about 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg,
22.5
mg, 25 mg, 27.5 mg, 30 mg, 32.5 mg, 35 mg, 37.5 mg, 40 mg, 45 mg, 50 mg, 60
mg, 70
mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg.
[0043] In embodiments in which the opioid is oxycodone hydrochloride,
the
total amount of oxycodone hydrochloride present in the pharmaceutical
composition
may range from about 2 mg to about 80 mg. In certain embodiments, the amount
of
oxycodone hydrochloride in the pharmaceutical composition may range from about
2
mg to about 10 mg, from about 10 mg to about 30 mg, or from about 30 mg to
about 80
mg. In specific embodiments, the amount of oxycodone hydrochloride present in
the
pharmaceutical composition may be about 5 mg, about 10 mg, about 15 mg, about
20
mg, about 30 mg, about 40 mg, about 60 mg, or about 80 mg.
[0044] In embodiments in which the opioid is oxymorphone
hydrochloride,
the total amount of oxymorphone hydrochloride present in the pharmaceutical
composition may range from about 2 mg to about 80 mg. In certain embodiments,
the
amount of oxymorphone hydrochloride present in the pharmaceutical composition
may
range from about 2 mg to about 10 mg, from about 10 mg to about 30 mg, or from
about
30 mg to about 80 mg. In specific embodiments, the amount of oxymorphone
hydrochloride present in the pharmaceutical composition may be about 5 mg,
about 10
mg, about 20 mg, about 30 mg, or about 40 mg.
17
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
(vi) Optional excipients
[0045] In various embodiments, the pharmaceutical compositions
disclosed herein may further comprise at least one additional pharmaceutically
acceptable excipient. Non-limiting examples of suitable excipients include
clay
minerals, binders, fillers, diluents, disintegrants, chelating agents,
flavoring agents,
coloring agents, taste masking agents, and combinations thereof.
[0046] In one embodiment, the optional excipient may be a clay
mineral.
A clay mineral refers to a hydrated aluminum phyllosilicate or a hydrated
magnesium
silicate comprising small insoluble particles. Mixing a clay mineral with a
suitable
solvent forms a colloidal dispersion of small particles that do not sediment.
Non-limiting
examples of suitable clay minerals include talc, bentonites, kaolinites,
nontronites,
montmorillonites, pyrophyllites, saponites, sauconites, vermiculites, and
combinations
thereof. In one iteration, the clay mineral may be powdered talc or micronized
talc.
[0047] In a further embodiment, the optional excipient may be a
binder.
Suitable binders include, but are not limited to, starches, pregelatinized
starches,
gelatin, polyvinylpyrolidone, cellulose, methylcellulose, sodium
carboxynnethylcellulose,
ethylcellulose, polyacrylamides, polyvinylalcohols, C12-C18 fatty acid
alcohols,
polyethylene glycols, polyols, saccharides, oligosaccharides, polypeptides,
peptides,
and combinations thereof.
[0048] In another embodiment, the optional excipient may be a filler.
Suitable fillers include, without limit, calcium carbonate, calcium phosphate,
calcium
sulfate, calcium silicate, magnesium carbonate, magnesium oxide, sodium
chloride,
starch, modified starches, cellulose, microcrystalline cellulose, sucrose,
lactose,
dextrose, mannitol, sorbitol, talc, and combinations thereof.
[0049] In another embodiment, the optional excipient may be a
diluent.
Non-limiting examples of diluents suitable for use include pharmaceutically
acceptable
saccharides such as sucrose, dextrose, lactose, microcrystalline cellulose,
cellulose,
cellulose derivatives, starches, fructose, xylitol, and sorbitol, polyhydric
alcohols, pre-
manufactured direct compression diluents, and mixtures of any of the
foregoing.
18
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
[0050] In a further embodiment, the optional excipient may be a
disintegrant. Examples of suitable disintegrants include, without limit,
crospovidone,
croscarnnellose sodium, sodium carboxynnethylcellulose, carboxynnethylcellose
calcium,
sodium starch glycolate, cellulose, microcrystalline cellulose,
methylcellulose, silicon
dioxide (also called colloidal silicone dioxide), alginates, clays, and
combinations of any
of the foregoing.
[0051] In an alternate embodiment, the optional excipient may be a
chelating agent. Non-limiting examples of suitable chelating agents include
ethylenediamine tetracetic acid (EDTA) and its salts, N-(hydroxy-
ethyl)ethylenediaminetriacetic acid, nitrilotriacetic acid (NIA), ethylene-
bis(oxyethylene-
nitrilo)tetraacetic acid, 1,4,7,10-tetraazacyclodo-decane-N,N',N",N"-
tetraacetic acid,
1,4,7,10-tetraaza-cyclododecane-N,N',N"-triacetic acid, 1,4,7-
tris(carboxymethyl)-10-(2'-
hydroxypropy1)- 1,4,7,10-tetraazocyclodecane, 1,4,7-triazacyclonane-N,N',N"-
triacetic
acid, 1,4,8,11 -tetraazacyclotetra-decane-N,N',N",N"-tetraacetic acid;
diethylenetriamine-pentaacetic acid (DTPA), ethylenedicysteine,
bis(aminoethanethiol)carboxylic acid, triethylenetetraamine-hexaacetic acid,
and 1,2-
diaminocyclohexane-N,N,N',N'-tetraacetic acid.
[0052] In a further embodiment, the optional excipient may be a
flavoring
agent. Flavoring agents may be chosen from synthetic flavor oils and flavoring
aromatics and/or natural oils, extracts from plants, leaves, flowers, fruits,
and
combinations thereof.
[0053] In still another embodiment, the optional excipient may be a
coloring agent. Suitable color additives include food, drug and cosmetic
colors (FD&C),
drug and cosmetic colors (D&C), or external drug and cosmetic colors (Ext.
D&C).
[0054] In yet another embodiment, the optional excipient may be a
taste-
masking agent. Taste-masking materials include, but are not limited to,
cellulose
ethers, polyethylene glycols, polyvinyl alcohol, polyvinyl alcohol and
polyethylene glycol
copolymers, monoglycerides or triglycerides, acrylic polymers, mixtures of
acrylic
polymers with cellulose ethers, cellulose acetate phthalate, and combinations
thereof.
19
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
[0055] The amount of the one or more additional excipients in the
pharmaceutical solid dosage form can and will vary depending upon the identity
of the
excipient and the identities and amounts of the other components of the
pharmaceutical
composition.
(vii) Optional film coating
[0056] In embodiments in which the pharmaceutical composition is an
oral
solid dosage form, the solid dosage form may further comprise a water-soluble
film
coating. Typically, the film coating comprises at least one hydrophilic
polymer, and the
coating does not affect the immediate release or abuse deterrent properties of
the
pharmaceutical composition. The film coating may provide moisture protection,
enhanced appearance, increased mechanical integrity, improved swallowability,
improved taste, and/or masking of odors.
[0057] Film coatings are well known in the art, e.g., some are
commercially available under the tradename OPADRY . Typically, a film coating
comprises at least one hydrophilic polymer and at least one plasticizer. Non-
limiting
examples of suitable polymers include hydroxypropylmethylcellulose,
hydroxypropylcellulose, hydroxypropylethylcellulose, ethylcellulose,
methylcellulose,
cellulose acetate phthalate, microcrystalline cellulose and carrageenan,
acrylic
polymers, polyvinyl alcohol, anionic and cationic polymers of methacrylic
acid,
copolymers of methacrylates, copolymers of acrylates and methacrylates,
copolymers
of ethacrylate and methylmethacrylate, polyvinylacetate phthalate, and
shellac.
Examples of suitable plasticizers include, without limit, triethyl citrate
(TEC),
acetyltriethyl citrate (ATEC), acetyl tri-n-butyl citrate (ATBC), dibutyl
sebacate, diethyl
phthalate, and triacetin. The film coating may optionally comprise additional
agents
such as a coloring agent, a filler, a flavoring agent, a taste-masking agent,
a surfactant,
an anti-tacking agent, and/or an anti-foaming agent. Suitable examples of
these agents
are well known in the art and/or are detailed above.
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
(viii) Specific embodiments
[0058] In specific embodiments, the pharmaceutical composition
comprises from about 5% to about 40% by weight of a non-cellulose
polysaccharide
chosen from glucomannan, xanthan gum, or combinations thereof; from about 10%
to
about 50% by weight of a hydrophilic gelling polymer chosen from polyethylene
oxide,
hydroxypropylmethylcellulose, hydroxypropyl cellulose, sodium carboxymethyl
cellulose,
or combinations thereof; from about 30% to about 60% by weight of an
effervescent
system comprising an organic acid and an alkali metal bicarbonate; and an API
chosen
from oxycodone, oxymorphone, hydrocodone, hydromorphone, codeine, or morphine.
(b) Dosage Forms
[0059] The physical form of the pharmaceutical composition disclosed
herein can and will vary. In general, the pharmaceutical composition is a
solid dosage
form that is formulated for oral administration. The solid dosage form may be
one of
various solid dosage units. Non-limiting examples of suitable solid dosage
units include
tablets, compacts, pellets, caplets, pills, and capsules. Such dosage units
may be
prepared using conventional methods known to those in the field of
pharmaceutical
formulation and described in pertinent texts, e.g., in Gennaro, A. R., editor.
"Remington:
The Science & Practice of Pharmacy", 21st ed., 2006, Williams & Williams, and
in the
"Physician's Desk Reference", 66th ed., 2014, PDR Staff.
[0060] In specific embodiments, the solid dosage unit may be a
tablet.
Non-limiting types of tablets include coated tablets, uncoated tablets,
compressed
tablets, compacted tablets, molded tablets, layered tablets, bilayer tablets,
extruded
tablets, multiparticulate tablets, monolithic tablets, and matrix tablets.
[0061] In embodiments in which the solid dosage form is a tablet, the
tablet generally has a friability of no greater than about 1.0%. In certain
embodiments,
the tablet may have a friability of less than about 1.0%, less than about
0.5%, less than
about 0.3%, less than about 0.2%, less than about 0.1%, less than about 0.05%,
or less
than about 0.01%. In exemplary embodiments, the tablet has a friability of
zero.
21
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
(c) In Vitro Release Properties
[0062] The pharmaceutical composition disclosed herein is formulated
such that the API is released rapidly from the composition. Thus, the
composition is
termed an immediate release pharmaceutical composition. As used herein,
"immediate
release" refers to an average release of at least 70% of the API within 45
minutes using
a USP approved in vitro release test. Unlike many immediate release
compositions, the
pharmaceutical composition disclosed herein comprises a blend of high
molecular
weight non-cellulose polysaccharide(s) and hydrophilic gelling polymer(s). The
disclosed composition, however, also comprises an effervescent system that
facilitates
ready dissolution of the composition and rapid release of the API from the
composition.
[0063] The in vitro dissolution of the API from the pharmaceutical
composition disclosed herein may be measured using an approved USP procedure.
For example, dissolution may be measured using an USP approved Type 2 paddle
apparatus, at a paddle speed of 50 rpm or 100 rpm, and a constant temperature
of 37
0.5 C. The dissolution test may be performed in the presence of 500 mL, 900
mL, or
1,000 mL of a suitable dissolution medium. Non-limiting examples of suitable
dissolution media include water, phosphate buffer (pH 6.8), acetate buffer (pH
4.5), and
0.1N HCI.
[0064] The pharmaceutical compositions disclosed herein provide
immediate release of the API. In some embodiments, the pharmaceutical
composition
may have an average release of about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,
90%, 95%, or 99% of the API within 45 minutes in the dissolution solution. In
other
embodiments, the pharmaceutical composition may have an average release of
about
50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% of the API within 30
minutes in the dissolution solution.
(d) Abuse Deterrent Properties
[0065] The solid dosage pharmaceutical compositions disclosed herein
also have abuse deterrent features. The combination of non-cellulose
polysaccharide(s) and hydrophilic gelling polymers along with the effervescent
system
22
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
imparts sufficient mechanical integrity (i.e., strength, hardness, etc.) to a
solid dosage
composition such the composition is resistant to crushing, grinding, cutting,
or
pulverizing to form a powder comprising small particles. Additionally, because
of the
presence of the non-cellulose polysaccharide(s) and the hydrophilic gelling
polymer(s),
a viscous mixture or gel forms when the solid dosage composition (or fractions
thereof)
is contacted with a small volume of a suitable solvent at a variety of
temperatures.
[0066] The mechanical integrity of the solid dosage pharmaceutical
composition may be assessed by measuring the hardness or crushing strength of
the
solid dosage composition. The hardness of the solid dosage composition may be
measured using any of numerous hardness testers, which are well known in the
art. In
general, the solid dosage composition has a hardness or crushing strength of
at least
kilopond (kp). In various embodiments, the solid dosage composition may have a
hardness or crushing strength ranging from about 10 kp to about 20 kp, from
about 20
kp to about 30 kp, from about 30 kp to about 40 kp, or more than about 40 kp.
In
certain embodiments, the hardness or crushing strength of solid dosage
composition is
less than about 50 kp.
[0067] The mechanical integrity of the solid dosage pharmaceutical
composition also may be assessed by measuring the particle size distribution
after
crushing, grinding, or pulverizing the composition in a suitable apparatus for
a specified
period of time. The solid dosage composition may be ground or milled in a
coffee
grinder, a spice grinder, a nut grinder, a coffee mill, a blender, a high-
shear mill, a ball
mill, a co-mill, a pill crusher, a tablet grinder, or another grinding/milling
apparatus. In
some embodiments, more than about 10%, more than about 20%, more than about
30%, more than about 40%, or more than about 50% of the particles formed when
the
solid dosage composition is subjected to 6 minutes of milling in a coffee
grinder or high
shear mill have an average diameter of greater than about 250 microns. In
other
embodiments, more than about 10%, more than about 20%, more than about 30%,
more than about 40%, or more than about 50% of the particles formed when the
solid
dosage composition is subjected to 3 minutes of milling in a coffee grinder or
high shear
mill have an average diameter of greater than about 250 microns. Because the
solid
23
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
dosage pharmaceutical composition disclosed herein is resistant to forming a
fine
powder by crushing, grinding or pulverizing, it deters abuse by inhalation.
[0068] Additionally, the solid dosage pharmaceutical composition
disclosed herein, whether whole, flattened, broken, crushed, or pulverized,
forms a
viscous mixture or gel when mixed with a small volume of a suitable solvent at
a variety
of temperatures. The volume of the suitable solvent may range from about 3 mL
to
about 15 mL. In some embodiments, the volume may be 5 mL, and in other
embodiments, the volume may be 10 mL. Suitable solvents include water,
alcohols
such as ethanol, acids such as acetic acid, fruit juice, and mixtures of any
of the
foregoing. The temperature of the extraction may range from about 4 C to about
100 C. In certain embodiments, the temperature of the extraction may be about
room
temperature (i.e., about 23-25 C), about 30 C, about 60 C, or about 90 C. The
duration of the extraction may range from about 5 minutes to about 3 hours. In
some
embodiments, the duration of the extraction may be about 30 minutes or about
60
minutes. The viscosity of the mixture or gel prevents the mixture or gel from
being
drawn through an injection syringe needle. Consequently, the pharmaceutical
compositions disclosed herein are resistant to abuse by extraction, filtering,
and/or
injection.
al) Processes for Preparing Solid Dosage Pharmaceutical Compositions
[0069] Another aspect of the disclosure encompasses processes for
preparing solid dosage forms of the pharmaceutical compositions disclosed
herein. The
processes comprise: (a) forming a mixture comprising at least one non-
cellulose
polysaccharide, at least one hydrophilic gelling polymer, and an effervescent
system;
(b) forming the mixture into a solid dosage unit; and (c) heating the solid
dosage unit to
form the solid dosage form. The solid dosage form optionally may be scored and
optionally may be coated with a water-soluble film coating.
24
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
(a) Forming a mixture
[0070] The first step of the process comprises forming a mixture
comprising the components of the pharmaceutical composition, which are
detailed
above in section (I)(a). In general, the mixture comprises at least one API,
at least one
non-cellulose polysaccharide, at least one hydrophilic gelling polymer, an
effervescent
system comprising an acid component and a base component, and a lubricant. The
components may be combined in any order or may be premixed in various
combinations before being combined together. For example, in one embodiment
the
acid component of the effervescent system may be co-processed with a
polyalkylene
glycol or poloxamer prior to being mixed with the rest of the components. In
another
embodiment, the API may be combined with some of the components before being
combined with the rest of the components. Thus, a variety of ordered mixing
schemes
are possible.
[0071] The mixture comprising the components of the pharmaceutical
composition may be formed by mixing, roller mixing, drum mixing, shear mixing,
dry
blending, chopping, milling, roller milling, granulating, dry granulating
(e.g., slugging or
roller compacting), wet granulating (e.g., fluid bed granulating, high shear
granulating),
and other mixing techniques known in the art.
(b) Forming a solid dosage unit
[0072] The process further comprises forming the mixture from step
(a)
into a solid dosage unit. Suitable solid dosage units are described above in
section
(I)(b). Means of forming solid dosage units are well known in the art. See,
e.g.,
Gennaro, A. R., editor. "Remington: The Science & Practice of Pharmacy", 21st
ed.,
2006, Williams & Williams, and in the "Physician's Desk Reference", 66th ed.,
2014,
PDR Staff. In specific embodiments, the solid dosage unit may be a tablet. The
tablet
may be a compression tablet, a molded tablet, a compacted tablet, or a pressed
tablet.
In exemplary embodiments, the tablet may be formed by direct compression. The
shape of the tablet may vary. Non-limiting tablet shapes include round, oval,
rectangular, and triangular. The size and mass of the tablet may vary. In
various
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
embodiments, the mass of the tablet may be range from about 100 mg to about
1000
mg. In exemplary embodiments, the mass of the tablet may range from about 300
mg
to about 500 mg. The solid dosage unit may be scored by selecting the
appropriate
dies and/or punches.
(c) Heating the solid dosage unit
[0073] The process further comprises heating the solid dosage unit
from
step (b). This heating step dries and cures the solid dosage unit, wherein the
cured
solid dosage form may have improved properties or characteristics relative to
an
uncured solid dosage unit. For example, the heating step may remove water from
the
solid dosage form, thereby protecting the effervescent system from premature
effervescence. Additionally, the heating step may plasticize some of the
polymers,
thereby leading to increased resistance to crushing/pulverization and/or to
more rapid
release of the API.
[0074] In general, the heating step occurs at a temperature of less
than
about 90 C. In various embodiments, the solid dosage unit may be heated at a
temperature from about 30 C to about 35 C, from about 35 C to about 40 C, from
about
40 C to about 45 C, from about 45 C to about 50 C, from about 50 C to about 55
C,
from about 55 C to about 60 C, from about 60 C to about 65 C, from about 65 C
to
about 70 C, from about 70 C to about 75 C, from about 75 C to about 80 C, from
about
80 C to about 85 C, or from about 85 C to about 90 C. In specific embodiments,
the
heating temperature may range from about 50 C to about 85 C.
[0075] The duration of the heating step can and will vary depending
upon
the components of the composition and the heating temperature. The duration of
the
heating step may range from about 10 minutes to about 20 hours. In some
embodiments, the duration of the heating step may range from about 10 to about
60
minutes, from about 1 to about 2 hours, from about 2 to about 3 hours, from
about 3 to
about 5 hours, from about 5 to about 10 hours, or from about 10 to about 20
hours. In
general, the higher the temperature, the shorter the duration of time for
heating.
26
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
[0076] In specific embodiments, the solid dosage unit may be heated
to a
temperature from about 65 C to about 80 C for a period of time ranging from
about 1
hour to about 3 hours.
(d) Optionally coating the solid dosage form
[0077] The solid dosage form may be coated with a film coating.
Suitable
film coatings are detailed above in section (I)(a)(viii). The optional coating
may be
applied to the solid dosage unit prior to the heating step, or the optional
coating may be
applied to the solid dosage form after the heating step.
DEFINITIONS
[0078] When introducing components of the embodiments described
herein, the articles "a", "an", "the" and "said" are intended to mean that
there are one or
more of the elements. The terms "comprising", "including" and "having" are
intended to
be inclusive and mean that there may be additional components other than the
listed
components.
[0079] If the components described herein have asymmetric centers,
all
chiral, diastereomeric, racemic forms and all geometric isomeric forms of a
structure are
intended, unless the specific stereochemistry or isomeric form is specifically
indicated.
[0080] As used herein, "abuse deterrent" refers to any property or
feature
of a pharmaceutical composition that lessens the potential for abuse of the
active
ingredient(s) in the composition.
[0081] The terms "gum" or "natural gum" refer to water-soluble and/or
water-swellable polysaccharides derived from natural sources, or structurally
modified
derivatives thereof, which are capable of forming highly viscous gels even at
low
concentrations.
[0082] The term "hydrophilic gelling polymer" refers to a polymer
with
affinity for water such that it readily absorbs water or an aqueous solution
and/or swells
when in contact with water or an aqueous solution to form a viscous mixture or
gel.
27
[0083] As used
herein, "immediate release" refers to an average release
of at least 70% of the API within 45 minutes using a USP approved in vitro
release
procedure.
[0084] Having described the invention in detail, it will be apparent
that
modifications and variations are possible without departing from the scope of
the
invention defined in the appended claims.
EXAMPLES
[0085] The following examples are included to illustrate, but not to
limit the
claimed pharmaceutical compositions and processes for making.
Example 1: Preparation of Formulations 1-3
[0086] A 50 g
batch of each formulation presented below in Table 1 was
prepared by combining all the components except magnesium stearate in a
plastic bag
and manually blending the mixture for 5 minutes. The magnesium stearate was
then
added and the mixture was blended for an additional 2-3 minutes. The blends
were
then compressed into oval tablets using a single-station Natoli tablet press
at a
compression force of about 21 kN. The tablets were placed in an aluminum pan
and
cured in a laboratory oven by heating at 80 C for 3 hours.
Table 1. Compositions of Formulations 1, 2, and 3
Ingredient Formulation 1 Formulation 2 Formulation 3
mg/tablet %w/w mg/tablet %w/w mg/tablet %w/w
Oxycodone HCI 30.84 6.56 30.84 6.17 30.84 5.51
L-(+)-Tartaric acid, extra 122.00 25.96 122.00 24.40 122.00
21.79
fine
PEG 3350 7.05 1.5 7.05 1.41 7.05 1.26
Effer-Soda 12 104.00 22.13 104.00 20.80 104.00
18.57
Polyox TM N10 LEO (100K) 103.40 22.00 103.40 20.68 103.40
18.46
Butylated hydroxytoluene 0.06 0.013 0.06 0.012 0.06 0.011
Citric acid, anhydrous 4.70 1.00 4.70 0.94 4.70 0.84
PolyoxTM WSR 301 NF 4.25 0.90 4.25 0.85 4.25 0.76
28
Date Recue/Date Received 2021-09-27
Table 1. Compositions of Formulations 1, 2, and 3
Ingredient Formulation 1 Formulation 2 Formulation 3
mg/tablet % w/w mg/tablet % w/w mg/tablet % w/w
LEO (4 million)
Glucomannan 90.60 19.28 120.60 24.12 120.60 21.54
KlucelTM HF (HPC) (1.15 0 0 0 0 60.00 10.71
million)
Magnesium stearate 3.10 0.66 3.10 0.62 3.10 0.55
Total 470.00
100.00 500.00 100.00 560.00 100.00
Example 2: Dissolution Analysis of Formulations 1-3
[0087] The in vitro release of oxycodone hydrochloride was determined
using an USP approved test. The dissolution parameters were: USP Apparatus
Type 2
(paddles), 50 rpm, and 500 mL water or 0.1 N HCI, at 37 0.5 C. The amount
of
oxycodone HCI in the dissolution fluid was determined at regular intervals.
The
dissolution data are presented in Tables 2 and 3. All three formulations
exhibited
immediate release of the active ingredient.
Table 2. Dissolution of Tablets in Water - Formulations 1 and 2
Time % Oxycodone HCI Dissolved
(minutes) Formulation 1 Formulation 2
Uncured Cured Tablet Uncured Cured
Tablet
Tablet Tablet
67.0 65.6 73.7 63.6
89.0 88.7 86.6 89.1
90.2 90.6 89.0 91.2
90.6 90.7 89.5 91.4
90.4 91.0 89.5 90.9
45 90.0 90.3 90.3 92.0
29
Date Recue/Date Received 2021-09-27
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
Table 3. Dissolution of Cured Tablets in 0.1 N
HCI - Formulations 2 and 3
Time % Oxycodone HCI Dissolved
(minutes) Formulation 2 Formulation 3
70.6 49.9
95.3 81.6
97.0 95.4
96.9 97.4
96.6 97.5
45 98.2 97.5
Example 3: Abuse Deterrence Tests ¨ Crushing
[0088] Cured tablets from Formulations 1-3 were milled under high-
shear
conditions with a Cuisinart DCG-20N coffee grinder. The grinder was paused for
30
seconds after each 30 seconds of milling for a total milling time of 3 minutes
(i.e., six
pulses of 30 seconds). The milled products were characterized by particle size
analysis. Table 4 presents the particle size data from the milling
experiments, with the
particle size reported as greater than 500 pm, from 250-500 pm, and less than
250 pm.
In general, particles greater than 250 pm are considered difficult to snort,
and hence,
formulations resulting in a large fraction of particles greater than 250 pm
are assumed
to have better deterrence against this route of abuse.
Table 4. Particle Size Distribution of Cured Tablets - Formulations 1-3
Weight fraction
>500 pm 250-500 pm <250 pm
Formulation 1 4.1 25.8 62.9
Formulation 2 3.3 26.7 66.6
Formulation 3 2.4 23.1 72.7
CA 02953396 2016-12-21
WO 2016/004170
PCT/US2015/038774
Example 4: Abuse Deterrence Tests ¨ Extraction with Solvents
[0089] Tablets from Formulations 1-3 were tested to determine how
much
oxycodone could be extracted with various solvents and at various
temperatures. The
less active ingredient that is extracted, the better deterrence provided by
the formulation
against abuse IV administration.
[0090] In one test, cured tablets from Formulations 2 and 3 were cut
into 8
pieces with a razor blade and the resultant pieces were extracted (no
stirring) with 5 mL
or 10 mL of water or 95% ethanol for 30 minutes at room temperature, 60 C, or
90 C.
At the end of the extraction period, the supernatant liquid was filtered
through a cotton
plug into a syringe. The amount of oxycodone HCI in the extract was determined
by
HPLC and expressed as a fraction of the total amount of oxycodone HCI in the
tablets.
The results are shown in Table 5.
Table 5. Extraction Data from Cut Tablets - Formulations 2 and 3
Sample Extraction Extraction Extraction Volume Amount of
Solvent Temperature Volume Recovered Oxycodone
(mL) (mL) Extracted
mg %
(in
theory)
F2 Water Room Temp 5 1.1 6.4 21.2
F3 Water Room Temp 5 0.6 4.0 13.4
F2 Water Room Temp 10 3.3 8.7 29.1
F3 Water Room Temp 10 1.4 4.1 13.7
F2 95% Et0H Room Temp 5 3.1 5.4 17.9
F3 95% Et0H Room Temp 5 3.1 3.0 10.0
F2 95% Et0H Room Temp 10 7.1 7.1 23.8
F3 95% Et0H Room Temp 10 7.1 4.0 13.5
F2 Water 90 C 5 0.6 2.4 7.9
31
CA 02953396 2016-12-21
WO 2016/004170
PCT/US2015/038774
Table 5. Extraction Data from Cut Tablets - Formulations 2 and 3
Sample Extraction Extraction Extraction Volume Amount of
Solvent Temperature Volume Recovered Oxycodone
(mL) (mL) Extracted
mg %
(in
theory)
F3 Water 90 C 5 0.9 3.1 10.3
F2 Water 90 C 10 4.4 11.8 39.3
F3 Water 90 C 10 3.6 9.7 32.3
F2 95% Et0H 60 C 5 3.1 9.0 29.9
F3 95% Et0H 60 C 5 2.9 7.6 25.4
F2 95% Et0H 60 C 10 7.2 9.0 30.2
F3 95% Et0H 60 C 10 6.8 6.4 21.3
[0091] In
another test, cured tablets from Formulations 1, 2, and 3 were
milled into particles as described above and the particles were extracted (no
stirring)
with 10 mL of water or 95% ethanol for 30 minutes at room temperature, 60 C,
or 90 C.
At the end of the extraction period, the supernatant liquid was filtered
through a cotton
plug into a syringe. The amount of oxycodone HCI in the extract was determined
by
HPLC and expressed as a fraction of the total amount of oxycodone HCI in the
tablets.
The results are shown in Table 6.
32
CA 02953396 2016-12-21
WO 2016/004170 PCT/US2015/038774
Table 6. Extraction Data from Pulverized Tablets - Formulations 1-3
Sample Extraction Extraction Volume
Amount of Oxycodone
Solvent Temperature Recovered Extracted
(mL) mg %
(in theory)
Fl Water Room Temp 7.8 11.21 37.4
F2 Water Room Temp 6.0 7.99 26.6
F3 Water Room Temp 6.5 6.18 20.6
Fl 95% Et0H Room Temp 7.0 4.39 14.6
F2 95% Et0H Room Temp 6.9 5.76 19.2
F3 95% Et0H Room Temp 6.3 7.40 24.7
Fl Water 90 C 8.2 17.40 58.0
F2 Water 90 C 8.2 12.24 40.8
F3 Water 90 C 8.1 9.50 31.7
Fl 95% Et0H 60 C 7.0 8.05 26.8
F2 95% Et0H 60 C 7.0 10.02 33.4
F3 95% Et0H 60 C 4.5 9.05 30.2
Example 5: Preparation of Formulations 4 and 5
[0092] Formulations were prepared, tableted, and cured essentially as
described in Example 1 using the ingredients listed in Table 7.
Table 7. Compositions of Formulations 4 and 5
Ingredient Formulation 4 Formulation 5
mg/tablet % w/w mg/tablet A w/w
Oxycodone 1-1CI 30.84 6.43 30.84 6.17
L-(+)-Tartaric acid, extra fine 122.00 25.42 122.00 24.40
PEG 3350 7.05 1.47 7.05 1.41
Effer-Soda 12 104.00 21.67 104.00 20.80
Polyox N10 LEO (100K) 103.40 21.54 103.40 20.68
33
Table 7. Compositions of Formulations 4 and 5
Ingredient Formulation 4 Formulation 5
mg/tablet % w/w mg/tablet % w/w
Butylated hydroxytoluene 0.06 0.01 0.06 0.01
Citric acid, anhydrous 4.70 0.98 4.70 0.94
PolyoxTM WSR 301 NF LEO (4M) 4.25 0.89 4.25 0.85
Glucomannan 40.00 8.33 60.00 12.00
Sodium carboxymethylcellulose 20.00 4.17 20.00 4.00
(30K)
MethocelTM K100M CR (250K) 30.00 6.25 30.00 6.00
Xanthan gum (Vanzan NF) 10.60 2.21 10.60 2.12
Magnesium stearate 3.10 0.65 3.10 0.62
Total 480.00 100.00
500.00 100.00
Example 6: Abuse Deterrence Tests - Extraction with Solvents
[0093] Cured
tablets from Formulations 4 and 5 were cut into 8 pieces
with a razor blade and the resultant pieces were extracted (no stirring) with
5 mL or 10
mL of water or 95% ethanol for 30 minutes at room temperature, 60 C, or 90 C.
At the
end of the extraction period, the supernatant liquid was filtered through a
cotton plug
into a syringe. The amount of oxycodone HCI in the extract was determined by
HPLC
and expressed as a fraction of the total amount of oxycodone HCI in the
tablets. The
results are shown in Table 8.
Table 8. Extraction Data from Cut Tablets - Formulations 4 and 5
Sample Extraction Extraction Extraction Volume Amount of
Solvent Temperature Volume Recovered Oxycodone
(mL) (mL) Extracted
mg %
(in
theory)
34
Date Recue/Date Received 2021-09-27
CA 02953396 2016-12-21
WO 2016/004170
PCT/US2015/038774
Table 8. Extraction Data from Cut Tablets - Formulations 4 and 5
Sample Extraction Extraction Extraction Volume Amount of
Solvent Temperature Volume Recovered Oxycodone
(mL) (mL) Extracted
mg %
(in
theory)
F4 Water Room Temp 5 0.9 3.1 10.3
F5 Water Room Temp 5 0.9 2.4 8.1
F4 Water Room Temp 10 2.9 6.4 21.2
F5 Water Room Temp 10 3.4 5.7 18.9
F4 95% Et0H Room Temp 5 3.1 5.3 17.8
F5 95% Et0H Room Temp 5 3.1 4.7 15.8
F4 95% Et0H Room Temp 10 7.2 6.4 21.2
F5 95% Et0H Room Temp 10 7.1 5.3 17.7
F4 Water 90 C 5 1.5 5.6 18.8
F5 Water 90 C 5 1.5 3.3 11.1
F4 Water 90 C 10 5.7 10.6 35.4
F5 Water 90 C 10 4.9 10.3 34.4
F4 95% Et0H 60 C 5 3.2 9.0 30.1
F5 95% Et0H 60 C 5 3.2 8.2 27.4
F4 95% Et0H 60 C 10 7.2 9.4 31.4
F5 95% Et0H 60 C 10 7.0 9.8 32.8
